S. Percy Ivy

Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors

R. Kurzrock, A. Naing, L. Camacho, 2014, Cancer.

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

E. Winer, O. Cohen, N. Lin, 2019, bioRxiv.

Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors

R. Kurzrock, A. Naing, L. Camacho, 2014, Cancer.